Summary:
- This study investigates the association between the use of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide and liraglutide—and the risk of developing suicidal ideation.
- Utilizing a large-scale analysis of electronic health records, the researchers conclude that there is no statistically significant evidence to suggest an increased risk of suicidal ideation among patients prescribed GLP-1 receptor agonists compared to those using other anti-obesity or anti-diabetes medications.